



For Immediate Release

DIMERIX RETAINS A CASH POSITION OF \$5.3 MILLION FOR DECEMBER QUARTER

MELBOURNE, Australia, 31 January 2019: Dimerix Limited (ASX: DXB) announced today a cash position of \$5.3 million at the end of the December quarter, which includes the R&D Tax Incentive refund of \$1,073,628 received in late December.

The Company is pleased to announce the cash neutral quarter while continuing to make excellent progress on our two Phase 2 Clinical studies in the areas of Kidney Disease: DMX-200 for Diabetic Kidney Disease; and DMX-200 for FSGS. The cash neutral December quarter is primarily as a result of actual R&D spend being lower than budgeted on the back of improved cost management and the R&D Tax Incentive refund.

Quarter highlights:

- New CEO and Managing Director transitions to full time role
- Receipt of R&D Tax Incentive refund of \$1,073,628
- Awarded \$50,000 Innovation Connection Grant
- First Patient dosed in DMX-200 Clinical Trial for FSGS
- Annual General Meeting held and all resolutions passed
- Received Orphan Drug Designation in EU
- First Patient dosed in DMX-200 Clinical Trial for Diabetic Kidney Disease

For further information, please visit our website at www.dimerix.com or contact the individuals outlined below.

—END—

At the Company
Dr Nina Webster, Dimerix Limited
Chief Executive Officer
Tel: 1300 813 321
E: investor@dimerix.com

Investor Relations
Glen Zurcher, IR Department
Account Director
Tel: +61 420 249 299
E: glen.zurcher@irdepartment.com.au

About Dimerix Bioscience Pty Ltd

Dimerix Limited's (ASX: DXB) wholly owned subsidiary Dimerix Bioscience Pty Ltd is a dynamic, clinical-stage drug development company, developing and commercialising patient-preferred and patent protected pharmaceutical products for global markets. Dimerix is currently developing its product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, termed Receptor-Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

Appendix 4C

+Rule 4.7B

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

DIMERIX LIMITED

ABN

Quarter ended ("current quarter")

18 001 285 230

31/12/2018

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1.0 Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for	-	-
(a) research and development	(583)	(1,073)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(328)	(526)
(f) administration and corporate costs	(192)	(472)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	5	11
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	1,074	1,074
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(24)	(986)

2.0 Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	(4)
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:	-	-
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	-	(4)

3.0	Cash flows from financing activities		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	-	-

4.0	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	5,335	6,284
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(24)	(986)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(4)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	16	33
4.6	Cash and cash equivalents at end of quarter	5,327	5,327

5.0	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	23	19
5.2	Call deposits	5,304	5,316
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,327	5,335

6.0 Payments to directors of the entity and their associates**Current quarter
\$A'000**

6.1 Aggregate amount of payments to these parties included in item 1.2

120

6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Payments represent director's fees.

7.0 Payments to related entities of the entity and their associates**Current quarter \$A'000**

7.1 Aggregate amount of payments to these parties included in item 1.2

7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8.0 Financing facilities available*Add notes as necessary for an understanding of the position*

8.1 Loan facilities

8.2 Credit standby arrangements

8.3 Other (please specify)

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be

**Total facility amount at
quarter end****\$A'000****Amount drawn at
quarter end****\$A'000**

entered into after quarter end, include details of those facilities as well.

9.0 Estimated cash outflows for next quarter**\$A'000**

9.1 Research and development

(1,257)

9.2 Product manufacturing and operating costs

-

9.3 Advertising and marketing

-

9.4 Leased assets

-

9.5 Staff costs

(220)

9.6 Administration and corporate costs

(393)

9.7 Other (provide details if material)

-

9.8 Total estimated cash outflows**(1,870)**

10.0	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity		
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:



Date: 31 January 2019

Company secretary

Print name:

Ian Hobson

Notes

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.